The IPO pipeline for the remainder of 2026 features dozens of scheduled listings through December, including ADARx Pharmaceuticals, Accelevation Holdings, Oura, and numerous SPAC combinations, following 247 U.S. IPOs year-to-date as of September 24. Activity has broadened beyond AI and biotech into consumer and financial names, yet Q3 proceeds of $34.9 billion fell short of expectations amid 19-year highs in Treasury yields, resumed rate-hike concerns, and AI spending caution. High-profile candidates such as OpenAI have deferred to 2027 to target $1 trillion valuations, while Anthropic eyes an October window and others like Databricks or Stripe remain unlikely before year-end. Market-implied odds reflect these timelines, with trader capital aggregating expectations around regulatory filings, earnings trajectories, and macroeconomic stability ahead of the December 31 resolution.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedPerplexity remains private with no confirmed IPO before the deadline
Available reporting continues to describe Perplexity as private and its CEO’s stated target as 2028. No official IPO completion or filing by the market deadline was found in the supplied material, supporting the low endpoint price.

































Beware of external links.
Beware of external links.
Frequently Asked Questions